Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma.

Andrew James MartinEmma GibbsKatrin SjoquistNick PavlakisJohn SimesTim PriceJenny ShannonSanjeev GillVikram JainGeoffrey LiuGeorge KannourakisYeul Hong KimJin Won KimDavid Goldsteinnull null

Published in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2017)

Regorafenib improved DFS without an excessively negative effect on QoL. Progressing development to the phase III setting is warranted.

Keyphrases

phase iii
open label
clinical trial
metastatic colorectal cancer
squamous cell carcinoma
randomized controlled trial
combination therapy
locally advanced